UY26454A1 - 4-CARBOXAMINE-1,2,3,4-TETRAHYDROKINOLINE 2-SUBSTITUTED CRYSTAL - Google Patents

4-CARBOXAMINE-1,2,3,4-TETRAHYDROKINOLINE 2-SUBSTITUTED CRYSTAL

Info

Publication number
UY26454A1
UY26454A1 UY26454A UY26454A UY26454A1 UY 26454 A1 UY26454 A1 UY 26454A1 UY 26454 A UY26454 A UY 26454A UY 26454 A UY26454 A UY 26454A UY 26454 A1 UY26454 A1 UY 26454A1
Authority
UY
Uruguay
Prior art keywords
tetrahydrokinoline
carboxamine
substituted crystal
crystals
substituted
Prior art date
Application number
UY26454A
Other languages
Spanish (es)
Inventor
Lyle Robinson Brostrom
Douglas John Meldrum Allen
Troy Anthony Appleton
Derek Lawrence Tickner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY26454A1 publication Critical patent/UY26454A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Se describen formas cristalinas de un inhibidor de CETP, procedimientos para preparar los cristales, procedimientos de uso de los cristales y composiciones farmacéuticas que contienen los cristales.Crystalline forms of a CETP inhibitor, methods of preparing the crystals, methods of using the crystals, and pharmaceutical compositions containing the crystals are described.

UY26454A 1999-11-30 2000-11-28 4-CARBOXAMINE-1,2,3,4-TETRAHYDROKINOLINE 2-SUBSTITUTED CRYSTAL UY26454A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
UY26454A1 true UY26454A1 (en) 2001-07-31

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26454A UY26454A1 (en) 1999-11-30 2000-11-28 4-CARBOXAMINE-1,2,3,4-TETRAHYDROKINOLINE 2-SUBSTITUTED CRYSTAL

Country Status (28)

Country Link
EP (1) EP1246804A1 (en)
JP (1) JP2003515592A (en)
KR (1) KR20020058057A (en)
CN (1) CN1402711A (en)
AP (1) AP2002002531A0 (en)
AU (1) AU1048801A (en)
BG (1) BG106854A (en)
BR (1) BR0015836A (en)
CA (1) CA2392979A1 (en)
CO (1) CO5271716A1 (en)
EA (1) EA200200510A1 (en)
EC (1) ECSP003792A (en)
EE (1) EE200200277A (en)
GT (1) GT200000199A (en)
HU (1) HUP0203521A2 (en)
IL (1) IL149097A0 (en)
IS (1) IS6338A (en)
MA (1) MA26845A1 (en)
MX (1) MXPA02005354A (en)
NO (1) NO20022558L (en)
OA (1) OA12099A (en)
PA (1) PA8506301A1 (en)
PE (1) PE20010904A1 (en)
PL (1) PL355892A1 (en)
TN (1) TNSN00231A1 (en)
TR (1) TR200201446T2 (en)
UY (1) UY26454A1 (en)
WO (1) WO2001040190A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
OA12619A (en) 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
GT200200170A (en) 2001-09-28 2003-05-23 PREPARATION OF INHIBITOR OF CETP ANHIDRO
DE60320940D1 (en) 2002-02-01 2008-06-26 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DISPERSIONS OF ACTIVE SUBSTANCES AND LIPOPHILIC MICROPHASE-BASED MATERIALS
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
WO2003063822A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
BR0306208A (en) 2002-08-30 2004-10-13 Japan Tobacco Inc Dibenzylamine compounds and their pharmaceutical use
JP2006508077A (en) 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド PGD2 receptor antagonist for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
CA2508840A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
MXPA05010456A (en) * 2003-03-28 2006-03-21 Pfizer Prod Inc 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity.
BRPI0413277A (en) 2003-08-04 2006-10-10 Pfizer Prod Inc pharmaceutical compositions of amorphous drug adsorbates and lipophilic microphase forming materials
MXPA06003927A (en) 2003-10-08 2008-02-07 Lilly Co Eli Compounds and methods for treating dyslipidemia.
JP4922924B2 (en) * 2004-04-13 2012-04-25 メルク・シャープ・エンド・ドーム・コーポレイション CETP inhibitor
JP2008504266A (en) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー Compounds and methods for treating dyslipidemia
US20070149567A1 (en) * 2004-09-23 2007-06-28 Pfizer Inc Quinoline compounds
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
CA2598133A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (en) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Method for inhibiting lipid absorption and lipid absorption inhibitor
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP2134169A2 (en) 2007-03-09 2009-12-23 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
AR077208A1 (en) 2009-06-30 2011-08-10 Lilly Co Eli ACID DERIVATIVES TRANS-4 - [[(5S) -5 - [[[3,5-BIS (TRIFLUOROMETIL) PHENYLE] METHYL] (2-METHYL-2H-TETRAZOL-5-IL) AMINO) -2,3, 4,5-TETRAHIDRO-7,9-DIMETIL-1H-1-BENZAZEPIN-1-IL) METHYL) -CYCLHEXANCARBOXYL AND ITS CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT, ITS USE TO PREPARE A MEDICAM
CN106559998B (en) 2014-07-30 2022-01-25 豪夫迈·罗氏有限公司 Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
AU5731098A (en) * 1997-02-03 1998-08-25 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
BR0015836A (en) 2002-08-06
OA12099A (en) 2006-05-04
PE20010904A1 (en) 2001-09-10
TR200201446T2 (en) 2002-11-21
IS6338A (en) 2002-04-12
BG106854A (en) 2002-12-29
ECSP003792A (en) 2002-04-23
CN1402711A (en) 2003-03-12
KR20020058057A (en) 2002-07-12
IL149097A0 (en) 2002-11-10
GT200000199A (en) 2002-05-23
EP1246804A1 (en) 2002-10-09
NO20022558D0 (en) 2002-05-29
MXPA02005354A (en) 2002-12-11
PA8506301A1 (en) 2002-08-26
CO5271716A1 (en) 2003-04-30
PL355892A1 (en) 2004-05-31
HUP0203521A2 (en) 2003-02-28
MA26845A1 (en) 2004-12-20
NO20022558L (en) 2002-05-29
WO2001040190A1 (en) 2001-06-07
TNSN00231A1 (en) 2002-05-30
JP2003515592A (en) 2003-05-07
EE200200277A (en) 2003-10-15
AU1048801A (en) 2001-06-12
CA2392979A1 (en) 2001-06-07
AP2002002531A0 (en) 2002-06-30
EA200200510A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
UY26454A1 (en) 4-CARBOXAMINE-1,2,3,4-TETRAHYDROKINOLINE 2-SUBSTITUTED CRYSTAL
ES2090713T3 (en) ORGANIC SALTS OF N, N'-DIACETIL-CYSTINE.
UY24555A1 (en) NEW COMPOUNDS
AR011069A1 (en) AMIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIARY COMPOUNDS, PHARMACEUTICAL FORMULATIONS THAT UNDERSTAND THEM, AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AS AN INHIBITOR OF NITRIC OXIDE, INDUCIBLE SYNTHESES.
ES2053451T3 (en) A PROCEDURE FOR THE PREPARATION OF A COMPOUND THAT HAS USEFUL PHARMACOLOGICAL PROPERTIES.
GT199900102A (en) PHENOXIPROPANOLAMINES, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
DK1007520T3 (en) 2-aminopyridines containing linked ring substituents as NOS inhibitors
ES2133543T3 (en) PIRROLIDINE AND OXAZOLIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF THE THROMBOCYTE AGGREGATION.
AR021355A1 (en) DERIVATIVES OF QUINOLINA. PROCEDURE FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM, AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINE
ES2134801T3 (en) CRYSTAL TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE.
NO934628L (en) Retroviral protease inhibitors
PA8586801A1 (en) HIV-INTEGRESS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE
ECSP034531A (en) SUBSTITUTED DERIVATIVES OF C-CICLOHEXILMETILAMINA
AR028443A1 (en) NEW COMPOUNDS DERIVED FROM PIPERAZINE AND PIPERIDINE, METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND PREPARATION OF THE SAME AND USE OF SUCH COMPOUNDS
DK0391171T3 (en) Use of di-styryl-phenyl-triglycol ether as crystallization inhibitor
HN2001000235A (en) DERIVATIVES BRIDGES OF PIPERAZINA
AR046131A1 (en) CRYSTAL FORMS OF {2- [1- (3,5- BISTRIFLUORUROMETILBENCIL) -5- PIRIDIN-4-IL-1H- [1,2,3] TRIAZOL- 4-IL] PIRIDIN- 3-IL} - (2- CHLOROPHENYL) METANONE
DK1051177T3 (en) Steroidal 3-O-Sulfamate derivatives as inhibitors of oestrone sulfatase
AR020563A1 (en) TIA-ALQUINOIC COMPOUNDS (POLI) AND THEIR DERIVATIVES, COMPOSITIONS THAT INCLUDE THEM AND THEIR USE
ES2186989T3 (en) MALTITOL CRYSTALS OF SPECIFIC FORMS, CRYSTAL COMPOUNDS THAT CONTAIN THEM AND PROCEDURES FOR THEIR PREPARATION.
BR9814495A (en) Compound, process to prepare it, use of it, pharmaceutical composition, and, process
PA8495001A1 (en) NEW CRYSTAL FORMS OF AN ANTIBIOTIC MACROLIDO.
AR002978A1 (en) Benzamide compounds, pharmaceutical compositions containing them, methods of preparing the same and the use thereof.
MX9400165A (en) DERIVATIVES OF TER-BUTYLERGOLINE, PROCESS FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
MX9200874A (en) COMPOUNDS OF A SPECIFIC COMPOSITION, A PROCEDURE FOR ITS PRODUCTION AND USE.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20120529